Influence of Cocaine Use Reduction on Markers of Immune Function

Overview

Journal J Neuroimmunol

Specialty Neurology

Date 2024 Nov 6

PMID 39504756

Authors

William W Stoops

Thomas P Shellenberg

Sean D Regnier

David H Cox

Reuben Adatorwovor

Lon R Hays

Danielle M Anderson

Joshua A Lile

Joy M Schmitz

Jennifer R Havens

Suzanne C Segerstrom

Affiliations

Soon will be listed here.

Abstract

This study determined the effects of reduced cocaine use on immune function. Treatment seeking participants with Cocaine Use Disorder enrolled in a 12-week contingency management trial to reduce cocaine use. Participants were randomly assigned 1:1:1 to High Value Reinforcers (i.e., $55/negative urine sample) for cocaine abstinence (n = 41), Low Value Reinforcers (i.e., $13/negative urine sample) for cocaine abstinence (n = 33) or Non-Contingent Control (n = 33). Immune measures were collected at 6-week intervals. The High Value group had greatest use reductions, increased erythema and IL-6 and decreased IL-10 and CCL5, suggesting an activated immune response. Cocaine use reduction may promote changes in immune health.

References

Feng F, Thompson M, Thomas B, Duffy E, Kim J, Kurosawa S . A computational solution to improve biomarker reproducibility during long-term projects. PLoS One. 2019; 14(4):e0209060. PMC: 6469750. DOI: 10.1371/journal.pone.0209060. View

Funchal G, Schuch J, Zaparte A, Sanvicente-Vieira B, Viola T, Grassi-Oliveira R . Cocaine-use disorder and childhood maltreatment are associated with the activation of neutrophils and increased inflammation. Acta Neuropsychiatr. 2023; 36(2):97-108. DOI: 10.1017/neu.2023.11. View

Van Dyke C, Stesin A, Jones R, Chuntharapai A, Seaman W . Cocaine increases natural killer cell activity. J Clin Invest. 1986; 77(4):1387-90. PMC: 424504. DOI: 10.1172/JCI112445. View

Anthony J, Vlahov D, Nelson K, Cohn S, Astemborski J, Solomon L . New evidence on intravenous cocaine use and the risk of infection with human immunodeficiency virus type 1. Am J Epidemiol. 1991; 134(10):1175-89. DOI: 10.1093/oxfordjournals.aje.a116021. View

Tardelli V, Bisaga A, Arcadepani F, Gerra G, Levin F, Fidalgo T . Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis. Psychopharmacology (Berl). 2020; 237(8):2233-2255. DOI: 10.1007/s00213-020-05563-3. View

Amin-Esmaeili M, Farokhnia M, Susukida R, Leggio L, Johnson R, Crum R . Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials. Addiction. 2024; 119(5):833-843. PMC: 11009085. DOI: 10.1111/add.16409. View

Longfield J, Margileth A, Golden S, Lazoritz S, Bohan J, Cruess D . Interobserver and method variability in tuberculin skin testing. Pediatr Infect Dis. 1984; 3(4):323-6. DOI: 10.1097/00006454-198407000-00010. View

Fox H, DSa C, Kimmerling A, Siedlarz K, Tuit K, Stowe R . Immune system inflammation in cocaine dependent individuals: implications for medications development. Hum Psychopharmacol. 2012; 27(2):156-66. PMC: 3674778. DOI: 10.1002/hup.1251. View

Kampman K . The treatment of cocaine use disorder. Sci Adv. 2019; 5(10):eaax1532. PMC: 6795516. DOI: 10.1126/sciadv.aax1532. View

10.

Dolan M, Clerici M, Blatt S, Hendrix C, Melcher G, Boswell R . In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis. 1995; 172(1):79-87. DOI: 10.1093/infdis/172.1.79. View

11.

Segerstrom S, Sephton S . Optimistic expectancies and cell-mediated immunity: the role of positive affect. Psychol Sci. 2010; 21(3):448-55. PMC: 3933956. DOI: 10.1177/0956797610362061. View

12.

Ruiz P, Cleary T, Nassiri M, Steele B . Human T lymphocyte subpopulation and NK cell alterations in persons exposed to cocaine. Clin Immunol Immunopathol. 1994; 70(3):245-50. DOI: 10.1006/clin.1994.1036. View

13.

Araos P, Pedraz M, Serrano A, Lucena M, Barrios V, Garcia-Marchena N . Plasma profile of pro-inflammatory cytokines and chemokines in cocaine users under outpatient treatment: influence of cocaine symptom severity and psychiatric co-morbidity. Addict Biol. 2014; 20(4):756-72. DOI: 10.1111/adb.12156. View

14.

Manini A, Gibson C, Miller M, Richardson L, Vargas-Torres C, Vedanthan R . Biomarkers of endothelial dysfunction in cocaine overdose and overdose-related cardiovascular events. Addict Biol. 2020; 26(2):e12901. PMC: 7572428. DOI: 10.1111/adb.12901. View

15.

Coller J, Hutchinson M . Implications of central immune signaling caused by drugs of abuse: mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence. Pharmacol Ther. 2012; 134(2):219-45. DOI: 10.1016/j.pharmthera.2012.01.008. View

16.

Ersche K, Hagan C, Smith D, Abbott S, Jones P, Apergis-Schoute A . Aberrant disgust responses and immune reactivity in cocaine-dependent men. Biol Psychiatry. 2013; 75(2):140-7. PMC: 3898808. DOI: 10.1016/j.biopsych.2013.08.004. View

17.

Ramasamy T, Doke M, McLaughlin J, Samikkannu T . Circadian disruption and psychostimulants dysregulates plasma acute-phase proteins and circulating cell-free mitochondrial DNA. Brain Behav Immun Health. 2023; 31:100659. PMC: 10344797. DOI: 10.1016/j.bbih.2023.100659. View

18.

Calipari E, Godino A, Peck E, Salery M, Mervosh N, Landry J . Granulocyte-colony stimulating factor controls neural and behavioral plasticity in response to cocaine. Nat Commun. 2018; 9(1):9. PMC: 5770429. DOI: 10.1038/s41467-017-01881-x. View

19.

Christou N, Meakins J, Gordon J, Yee J, Nohr C, Shizgal H . The delayed hypersensitivity response and host resistance in surgical patients. 20 years later. Ann Surg. 1995; 222(4):534-46; discussion 546-8. PMC: 1234888. DOI: 10.1097/00000658-199522240-00011. View

20.

Donovan D, Bigelow G, Brigham G, Carroll K, Cohen A, Gardin J . Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. Addiction. 2011; 107(4):694-708. PMC: 3537825. DOI: 10.1111/j.1360-0443.2011.03473.x. View